Related Experiment Video

Updated: Sep 5, 2025

Author Spotlight: Studying the Impact of Maternal Dietary Deficiencies on Long-Term Offspring Health Outcomes
03:19

Author Spotlight: Studying the Impact of Maternal Dietary Deficiencies on Long-Term Offspring Health Outcomes

Published on: June 28, 2024

492

Effect of clofibrate on reducing neonatal jaundice: a systematic review and meta-analysis

Fatemeh Eghbalian1, Lotfollah Karimi2, Roya Raeisi1

  • 1Department of Pediatrics, Hamadan University of Medical Sciences, Hamadan, Iran.

Osong Public Health and Research Perspectives
|July 12, 2022
PubMed

Insights

Clofibrate effectively reduces neonatal jaundice by lowering bilirubin levels. This treatment also decreases hospitalization duration, costs, and associated side effects in newborns.

Area of Science:

  • Neonatal Medicine
  • Pharmacology
  • Biochemistry

Background:

  • Neonatal jaundice, characterized by bilirubin deposition in tissues, signals bilirubin excretion disorders.
  • Early detection and intervention are crucial for managing neonatal hyperbilirubinemia.

Purpose of the Study:

  • To systematically review the efficacy of clofibrate in reducing neonatal jaundice.
  • To evaluate clofibrate's impact on total serum bilirubin levels and clinical outcomes.

Main Methods:

  • A systematic review of international databases (PubMed, Scopus, Web of Science, Embase, Cochrane, Google Scholar) was conducted.
  • Included 17 studies with 665 neonates, published between 2005-2019.
  • Analyzed clofibrate doses ranging from 25-100 mg/kg body weight.

Main Results:

  • Clofibrate significantly decreased total serum bilirubin levels in neonates at 24, 36, 48, and 72 hours post-treatment.
  • The reduction in bilirubin was particularly notable from the second day of treatment onwards.
  • Clofibrate administration was associated with reduced hospitalization time, lower hospital costs, and fewer side effects.

Conclusions:

  • Clofibrate demonstrates significant efficacy in treating neonatal jaundice.
  • The drug offers a promising therapeutic option for reducing hyperbilirubinemia and improving clinical outcomes in neonates.

Keywords:
ClofibrateHyperbilirubinemiaJaundiceNeonatal jaundice

More Related Videos

Isolation of Neonatal Extrahepatic Cholangiocytes07:54

Isolation of Neonatal Extrahepatic Cholangiocytes

Published on: June 5, 2014

10.4K
Biochemical Measurement of Neonatal Hypoxia13:13

Biochemical Measurement of Neonatal Hypoxia

Published on: August 24, 2011

14.1K

Related Concept Videos

Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
209
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
852
Hepatic Drug Clearance: Effect of Protein Binding01:09

Hepatic Drug Clearance: Effect of Protein Binding

Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
284
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
662
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.7K
Overview of Fatty Acid Metabolism01:28

Overview of Fatty Acid Metabolism

Lipids also are sources of energy that power cellular processes. Like carbohydrates, lipids are composed of carbon, hydrogen, and oxygen, but these atoms are arranged differently. Most lipids are nonpolar and hydrophobic. Major types include fats and oils, waxes, phospholipids, and steroids.
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
31.6K